U.S. Bacterial Conjunctivitis Drugs Market

Table of Content

Chapter 1 Preface

1.1 Report Description

1.2 Market Segmentation

1.3 Research Methodology

1.4 Assumptions

Chapter 2 Executive Summary

2.1 Market Snapshot: U.S. Bacterial Conjunctivitis Drugs Market

Chapter 3 U.S. Bacterial Conjunctivitis Drugs Market Overview

3.1 Market Dynamics and Overview

3.2 Incidence Rate of Bacterial Conjunctivitis in the U.S.

3.3 Market Drivers

      3.3.1 Rising Incidence of Ophthalmic Bacterial Infection

      3.3.2 Susceptibility Among Various Age Groups Ranging from Neonates to Geriatrics

3.4 Market Restraints

      3.4.1 Increasing Genericization of Antibacterial Drugs Could Lead to a Crowded and Unprofitable Market

      3.4.2 Upcoming Patent Expirations likely to Hinder Market Growth

      3.4.3 Burgeoning Multi-Drug Resistant Bacterial Strains Expected To Hinder Market Growth

3.5 Market Opportunities

      3.5.1 Implementation of Product Development Partnerships (PDPs) Business Models

      3.5.2 Focus on Designing and Producing Combination Drug Products

3.6 Event Impact Assessment: U.S. Bacterial Conjunctivitis Market

3.7 Regulatory Framework

3.8 Patents and Patent Challenges: Overview

3.9 List of API Manufacturers

3.10 Key Discontinued Products: U.S. Bacterial Conjunctivitis Drugs Market

      3.10.1 Oxytetracycline/Polymyxin B

      3.10.2 Sulfisoxazole Ophthalmic

      3.10.3 Phenylephrine/Sulfacetamide Sodium

      3.10.4 Chloramphenicol

3.11 Market Attractiveness Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Type

3.12 Market Share Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Key Players, 2013 (Value %)

Chapter 4 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class

4.1 Overview

      4.1.1 Recommended Dosages for Treatment of Bacterial Conjunctivitis

      4.1.2 U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2012 – 2024 (USD Million)

4.2 Fluoroquinolones

      4.2.1 Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million)

      4.2.2 Ciprofloxacin

                4.2.2.1 U.S. Ciprofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

      4.2.3 Ofloxacin

                4.2.3.1 U.S. Ofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

      4.2.4 Levofloxacin

                4.2.4.1 U.S. Levofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

      4.2.5 Moxifloxacin

                4.2.5.1 U.S. Moxifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

      4.2.6 Gatifloxacin

                4.2.6.1 U.S. Gatifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

      4.2.7 Besifloxacin

                4.2.7.1 U.S. Besifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

4.3 Aminoglycosides

      4.3.1 Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million)

      4.3.2 Tobramycin

                4.3.2.1 U.S. Tobramycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

      4.3.3 Gentamycin

                4.3.3.1 U.S. Gentamycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

4.4 Macrolides

      4.4.1 Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2024 (USD Million)

      4.4.2 Erythromycin

                4.4.2.1 U.S. Erythromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

      4.4.3 Azithromycin

                4.4.3.1 U.S. Azithromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

4.5 Others (Bacitracin, Doxycycline, Polymyxin, and Fusidic Acid)

                4.5.1.1 U.S. Others Market Revenue, by Bacterial Conjunctivitis, 2012 – 2024 (USD Million)

Chapter 5 U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment

5.1 Overview

5.2 Vancomycin Ophthalmic Ointment

      5.2.1 U.S. Vancomycin Ophthalmic Ointment for Bacterial Conjunctivitis Market Revenue, 2019 – 2024 (USD Million)

5.3 Early Stage (Phase I and Phase II trials) – Tabular Representation

Chapter 6 Recommendations

Chapter 7 Company Profiles

7.1 Actavis plc (now Allergan plc)

      7.1.1 Company Overview

      7.1.2 Financial Overview

      7.1.3 Product Portfolio

      7.1.4 Business Strategies

      7.1.5 Recent Developments

7.2 Akorn, Inc.

      7.2.1 Company Overview

      7.2.2 Financial Overview

      7.2.3 Product Portfolio

      7.2.4 Business Strategies

      7.2.5 Recent Developments

7.3 Bayer AG

      7.3.1 Company Overview

      7.3.2 Financial Overview

      7.3.3 Product Portfolio

      7.3.4 Business Strategies

      7.3.5 Recent Developments

7.4 F. Hoffmann-La Roche Ltd.

      7.4.1 Company Overview

      7.4.2 Financial Overview

      7.4.3 Product Portfolio

      7.4.4 Business Strategies

      7.4.5 Recent Developments

7.5 Merck & Co., Inc.

      7.5.1 Company Overview

      7.5.2 Financial Overview

      7.5.3 Product Portfolio

      7.5.4 Business Strategies

      7.5.5 Recent Developments

7.6 Novartis AG

      7.6.1 Company Overview

      7.6.2 Financial Overview

      7.6.3 Product Portfolio

      7.6.4 Business Strategies

      7.6.5 Recent Developments

7.7 Perrigo Company plc

      7.7.1 Company Overview

      7.7.2 Financial Overview

      7.7.3 Product Portfolio

      7.7.4 Business Strategies

      7.7.5 Recent Developments

7.8 Pfizer, Inc.

      7.8.1 Company Overview

      7.8.2 Financial Overview

      7.8.3 Product Portfolio

      7.8.4 Business Strategies

      7.8.5 Recent Developments

7.9 Santen Pharmaceutical Co., Ltd.

      7.9.1 Company Overview

      7.9.2 Financial Overview

      7.9.3 Product Portfolio

      7.9.4 Business Strategies

      7.9.5 Recent Developments

7.10 Valeant Pharmaceuticals International, Inc.

      7.10.1 Company Overview

      7.10.2 Financial Overview

      7.10.3 Product Portfolio

      7.10.4 Business Strategies

      7.10.5 Recent Developments

List of Tables

List of Tables

TABLE 1: Market Snapshot: U.S. Bacterial Conjunctivitis Drugs Market

TABLE 2: Upcoming Patents Expiration of Branded Bacterial Conjunctivitis Drugs and Competing Companies of Generic Products

TABLE 3: List of Ciprofloxacin API Manufacturers

TABLE 4: List of Ofloxacin API Manufacturers

TABLE 5: List of Levofloxacin API Manufacturers

TABLE 6: List of Moxifloxacin API Manufacturers

TABLE 7: List of Gatifloxacin API Manufacturers

TABLE 8: List of Besifloxacin API Manufacturers

TABLE 9: List of Tobramycin API Manufacturers

TABLE 10: List of Gentamycin API Manufacturers

TABLE 11: List of Erythromycin API Manufacturers

TABLE 12: List of Azithromycin API Manufacturers

TABLE 13: List of Bacitracin API Manufacturers

TABLE 14: List of Neomycin API Manufacturers

TABLE 15: List of Fusidic Acid API Manufacturers

TABLE 16: Recommended Dosages for Treatment of Bacterial Conjunctivitis

TABLE 17: U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2012 – 2018 (USD Million)

TABLE 18: U.S. Bacterial Conjunctivitis Drugs Market Revenue, by Drug Class, 2019 – 2024 (USD Million)

TABLE 19: Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2018 (USD Million)

TABLE 20: Fluoroquinolones for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 – 2024 (USD Million)

TABLE 21: Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2018 (USD Million)

TABLE 22: Aminoglycosides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 – 2024 (USD Million)

TABLE 23: Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2012 – 2018 (USD Million)

TABLE 24: Macrolides for Bacterial Conjunctivitis Market Revenue, by Drug Class, 2019 – 2024 (USD Million)

TABLE 25: Early Stage (Phase I and Phase II trials) – Tabular Representation

TABLE 26: Actavis plc: Expenses & Revenue, 2011 – 2013 (USD Million)

TABLE 27: Novartis AG: Expenses & Revenue, 2011 – 2013 (USD Million)

List of Chart

List of Figures

FIG. 1: U.S. Bacterial Conjunctivitis Drugs Market Segmentation

FIG. 2: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class, 2013 (USD Million)

FIG. 3: U.S. Bacterial Conjunctivitis Drugs Market: Drivers, and Restraints

FIG. 4: Market Attractiveness Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class

FIG. 5: Market Share Analysis: U.S. Bacterial Conjunctivitis Drugs Market, by Key Players, 2013 (Value %)

FIG. 6: U.S. Ciprofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 7: U.S. Ofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 8: U.S. Levofloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 9: U.S. Moxifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 10: U.S. Gatifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 11: U.S. Besifloxacin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 12: U.S. Tobramycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 13: U.S. Gentamycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 14: U.S. Erythromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 15: U.S. Azithromycin for Bacterial Conjunctivitis Market Revenue, 2012 – 2024 (USD Million)

FIG. 16: U.S. Others Market Revenue, by Bacterial Conjunctivitis, 2012 – 2024 (USD Million)

FIG. 17: U.S. Vancomycin Ophthalmic Ointment for Bacterial Conjunctivitis Market Revenue, 2019 – 2024 (USD Million)

FIG. 18: Actavis plc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 19: Akorn, Inc.: Annual Revenue, 2011 – 2013 (USD million)

FIG. 20: Bayer AG (Bayer HealthCare): Annual Revenue, 2011 – 2013 (USD Million)

FIG. 21: F. Hoffmann-La Roche Ltd.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 22: Annual Revenue: Merck & Co., Inc., 2011 – 2013 (USD Million)

FIG. 23: Novartis AG: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 24: Perrigo Company plc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 25: Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

FIG. 26: Santen Pharmaceutical Co., Ltd.: Annual Revenue, 2011 – 2013 (USD million)

FIG. 27: Valeant Pharmaceuticals International, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

Description

The U.S. bacterial conjunctivitis drugs market is exhaustively examined and analyzed in a recently published report by Persistence Market Research. The forecast period for this market research is 2012-2024; however, 2012 is take as the historical year and 2013 is considered as the base year for calculating market values.

The first part of the report features market overview, followed by a section on key drivers and another section on key restraints. The key drivers section focuses on the factors that contribute to market growth, whereas the restraints section includes the factors that are responsible for the declining growth prospects.

This report offers a study on the entire market analysis conducted for various antibacterial drug classes that are commonly prescribed for the treatment of bacterial conjunctivitis. The segmentation based on the drug class includes four key segments and the drugs that fall under respective classes. The report elaborates each of them, providing an in-depth data about their historic, current, and estimated status in the market along with the factors associated with their market condition. Apart from existing large companies involved in pharmaceutical commercialization, new entrants in the U.S. market can also grasp valuable insights from this report.

The last section of the report constitutes the analysis of key players and offers an extensive overview of all the dominating companies competing in the U.S. market for bacterial conjunctivitis dugs. Most of them are increasingly seeking market expansion through strategic mergers and acquisitions. They are also striving for better, strengthened distribution network for enhanced operations across the U.S. market. The report also features a range of market trends and upcoming opportunities.

Research Methodology

To deduce the U.S. bacterial conjunctivitis drugs market size, the report considers various aspects based on secondary research. Furthermore, key data points such as region-wise split and market split by the drug class; and qualitative inputs from primary respondents have been incorporated to arrive at appropriate market estimates. The forecast presented in the report assesses the total revenue generated and expected revenue contribution in the U.S. bacterial conjunctivitis drugs market.

The report begins with sizing the market in terms of value and volume for the base year, which forms the basis for forecasting how the market is anticipated to take shape in the near future. Given the characteristics of the market, gathered data is triangulated via different analysis based on supply side and demand side drivers and other key dynamics of the U.S. bacterial conjunctivitis drugs market.

To develop the market forecast, Persistence Market Research has also conducted a factor analysis to understand the impact of various forces/factors on the target market. The report provides forecasts not only in terms of CAGR but also presents a detailed analysis based on key parameters such as Year-on-Year (Y-o-Y) growth to understand market predictability and to identify the right opportunities.

Another key feature of this report is an analysis of the U.S. bacterial conjunctivitis drugs market and the corresponding revenue forecast in terms of absolute dollar opportunity, usually overlooked while forecasting the market. However, absolute dollar opportunity is critical in assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales perspective in the U.S. bacterial conjunctivitis drugs market.

Further, to understand key segments in terms of their growth and overall U.S. bacterial conjunctivitis drugs market performance, Persistence Market Research has developed a market attractiveness index to help providers identify existing market opportunities in the U.S. bacterial conjunctivitis drugs market.